• Product
• KPA, “to discuss ingredient prescribing in upcoming FAPA"
• by Kim JiEun Mar 5, 2024 05:49am

• Company
• Kolon Life Science appeals to the Supreme Court for Invossa
• by Nho, Byung Chul Mar 5, 2024 05:49am

• Company
• Hugel receives FDA approval for its botulinum toxin Letybo
• by Nho, Byung Chul Mar 5, 2024 05:48am

• Company
• New multiple myeloma Ab ‘Elrexfio’ expects to enter KOR
• by Eo, Yun-Ho Mar 5, 2024 05:48am

• Policy
• Will Ferinject be reimbursed this time?
• by Lee, Tak-Sun Mar 5, 2024 05:48am

• Company
• Intensifying competition in ulcerative colitis drug market
• by Son, Hyung-Min Mar 4, 2024 05:53am

• Policy
• Guideline to be revised to prevent unintentional impurities
• by Lee, Hye-Kyung Mar 4, 2024 05:52am

• Company
• Generics of ‘Opsumit’ face tough competition in KOR
• by Kim, Jin-Gu Mar 4, 2024 05:52am

• Company
• Bayer releases 2 new CVD drugs with reimb in KOR
• by Eo, Yun-Ho Mar 4, 2024 05:52am

• Policy
• Will the novel anticancer drug Enhertu be reimb in April?
• by Lee, Tak-Sun Mar 4, 2024 05:52am